Discontinued — last reported Q4 '25
McKesson Acquisitions decreased by 82.6% to $4.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 81.0%, from $21.00M to $4.00M. Over 4 years (FY 2022 to FY 2026), Acquisitions shows an upward trend with a 388.5% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.00M | $3.00M | $2.00M | $0.00 | $1.00M | $22.00M | $833.00M | $11.00M | $0.00 | $0.00 | $6.00M | $266.00M | $0.00 | $1.00M | $2.00M | $21.00M | $3.36B | $30.00M | $23.00M | $4.00M |
| QoQ Change | — | +200.0% | -33.3% | -100.0% | — | >999% | >999% | -98.7% | -100.0% | — | — | >999% | -100.0% | — | +100.0% | +950.0% | >999% | -99.1% | -23.3% | -82.6% |
| YoY Change | — | — | — | — | +0.0% | +633.3% | >999% | — | -100.0% | -100.0% | -99.3% | >999% | — | — | -66.7% | -92.1% | — | >999% | >999% | -81.0% |